ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Rhea-AI Summary

ADC Therapeutics SA (NYSE: ADCT) announced its executives will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 1:40 pm ET. The event can be accessed via a live webcast on the company's Investors page, with a replay available for 30 days. ADC Therapeutics focuses on innovative antibody drug conjugates for treating hematologic malignancies and solid tumors, including FDA-approved ZYNLONTA for lymphoma.

LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that its executives will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 1:40 pm ET.

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days.

About ADC Therapeutics

ADC Therapeutics (NYSE: ADCT) is a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs). The Company is advancing its proprietary PBD-based ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.

ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) is approved by the FDA for the treatment of relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents. Cami (camidanlumab tesirine) is being evaluated in a pivotal Phase 2 trial for relapsed or refractory Hodgkin lymphoma and in a Phase 1b clinical trial for various advanced solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and has operations in London, the San Francisco Bay Area and New Jersey. For more information, please visit https://adctherapeutics.com/ and follow the Company on Twitter and LinkedIn.

ZYNLONTA^® is a registered trademark of ADC Therapeutics SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005296/en/

Investors

Eugenia Litz

ADC Therapeutics

Eugenia.Litz@adctherapeutics.com

+44 7879 627205

Amanda Hamilton

ADC Therapeutics

amanda.hamilton@adctherapeutics.com

+1 917-288-7023

EU Media

Alexandre Müller

Dynamics Group

amu@dynamicsgroup.ch

+41 (0) 43 268 3231

USA Media

Mary Ann Ondish

ADC Therapeutics

maryann.ondish@adctherapeutics.com

+1 914-552-4625

Source: ADC Therapeutics SA

FAQ

When will ADC Therapeutics participate in the BofA Securities 2022 Healthcare Conference?

ADC Therapeutics will participate in the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 1:40 pm ET.

How can I watch the ADC Therapeutics presentation at the healthcare conference?

You can watch the ADC Therapeutics presentation via a live webcast available on their Investors page.

What is ZYNLONTA, and what is its significance for ADC Therapeutics?

ZYNLONTA (loncastuximab tesirine-lpyl) is ADC Therapeutics' FDA-approved treatment for relapsed or refractory diffuse large b-cell lymphoma after two or more lines of systemic therapy.

What types of products does ADC Therapeutics develop?

ADC Therapeutics develops next-generation targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors.

Where is ADC Therapeutics headquartered?

ADC Therapeutics is headquartered in Lausanne, Switzerland, with operations in London, the San Francisco Bay Area, and New Jersey.